Related by context. All words. (Click for frequent words.) 77 KRAS gene 73 K RAS 72 FLT3 70 KRAS mutations 70 K ras gene 70 type KRAS 70 IGF IR 70 K ras mutations 70 KRAS mutation 69 V#F mutation 68 ABCB1 67 T#I [002] 67 KRAS 67 EGFR mutation 67 cyclin E 67 JAK2 67 mCRC patients 66 PKCi 66 promoter methylation 66 Estrogen Receptor 66 p# biomarker 66 EGFR mutations 66 Gleevec resistant 66 XmAb# 66 BCR ABL 66 gefitinib Iressa 66 PIK3CA 66 MGMT gene 65 TTR gene 65 differentially expressed genes 65 ERBB2 65 JAK2 V#F 65 mutated K ras 65 haematopoietic 65 UGT#A# 65 BRAF mutation 65 cMET 65 adipogenic 65 VKORC1 65 BRAF V#E mutation 65 MAPK pathway 65 mutant KRAS 65 alkaline phosphatase ALP 65 CYP#C# [002] 65 NSCLC tumors 65 activating mutations 64 NPM1 64 Epidermal Growth Factor Receptor 64 hTERT 64 mutant p# 64 decitabine 64 mutant BRAF 64 estrogen receptor ER 64 selective modulator 64 Clusterin 64 cancer mCRC 64 KRAS mutant 64 ovarian carcinoma 64 circulating endothelial cells 64 lymphoid malignancies 64 hENT1 64 HER2 overexpression 64 LRP6 64 HIF 1alpha 64 RRM1 64 epithelial tumors 64 miRNA expression 64 constitutively active 64 CYP#D# genotype 64 WT1 64 MAGE A3 63 TNFalpha 63 CCR9 63 factor receptor EGFR 63 LRP5 63 HER2/neu 63 TPMT 63 tyrosine phosphorylation 63 AGTR1 63 prostate carcinoma 63 eIF 4E 63 KRAS status 63 gene rearrangements 63 Her2/neu 63 retinoic acid receptor 63 diagnostic biomarker 63 imatinib resistant 63 JAK2 kinase 63 breast carcinoma 63 EGFR tyrosine kinase inhibitors 63 prognostic markers 63 carcinoembryonic antigen 63 urothelial carcinoma 63 immunohistochemical 63 KLF4 63 EGFR 63 proto oncogene 63 E#F# 63 hypermethylation 63 5alpha reductase 63 histone deacetylase inhibitor 63 splice variants 63 receptor tyrosine kinase inhibitor 63 EGFr 63 tumorigenicity 63 androgen receptor AR 63 prognostic marker 63 NGAL 63 activin 63 TACI Ig 63 HIF 1a 63 MTHFR 63 prostate cancer CaP 63 KRAS wild 63 inducible nitric oxide synthase 63 prognostic biomarker 63 malignant transformation 63 PTPN# 63 gastrointestinal stromal tumors GISTs 63 BMP2 63 hepatoma 63 Allogeneic 63 mutant alleles 62 Leukemias 62 CXCR7 62 pharmacodynamic biomarkers 62 KRAS oncogene 62 CYP#C# [001] 62 TEL AML1 62 cisplatin resistant 62 Flt3 62 cellular prion protein 62 hepatocyte 62 Foxp3 62 RAV# 62 HER2 neu 62 constitutively activated 62 pancreatic islet 62 XL# inhibits 62 hypomethylation 62 pancreatic adenocarcinoma 62 transgene expression 62 cells hESCs 62 GISTs 62 virulence genes 62 c MYC 62 NPM1 mutations 62 glycosylated 62 TOP2A 62 genomic alterations 62 EpCAM 62 FGFR3 62 Granulocyte Colony Stimulating Factor 62 gene locus 62 FLT3 ITD 62 recurrent glioblastoma multiforme 62 cathepsins 62 steroidogenesis 62 p#INK#a 62 EGFRvIII 62 EGFR protein 62 MicroRNA 62 hypermethylated 62 Immunohistochemical staining 62 TMPRSS2 ERG fusion 62 GSTP1 62 effector function 62 lymphoid cells 62 predictive biomarker 62 NKX#.# 62 PDGF receptor 62 kinase inhibition 62 ERK signaling 62 gastric adenocarcinoma 62 transgenic mouse models 62 Immunohistochemical analysis 62 gastric carcinoma 62 RAR beta 62 PC3 cells 62 immunohistochemical analysis 62 cilengitide 62 HER2 expression 62 JAK3 62 vivo validation 62 TIMP 1 62 tumor subtypes 62 BCL#A 62 HBx 62 proteolytic cleavage 62 Velcade bortezomib 62 pancreatic islet cell 62 SIRT2 62 T#I mutant 62 ALN TTR 61 trans retinoic acid 61 posaconazole 61 CDKN2A 61 lymphoma subtypes 61 gene amplification 61 Xanafide 61 microdeletions 61 MGd 61 mutated KRAS gene 61 IFN gamma 61 metastatic renal cell carcinoma 61 sipuleucel T 61 adenocarcinomas 61 Jhdm2a 61 IL#B 61 SOX9 61 interleukin IL -# 61 beta1 integrin 61 histologies 61 melatonin receptor 61 osteoblast 61 epigenetic therapies 61 transgenic rats 61 downregulated 61 microRNA expression 61 Symadex 61 RhuDex R 61 hematological parameters 61 PNH patients 61 GPR# [001] 61 EGFR HER2 61 survivin 61 mTOR inhibitors 61 imatinib resistance 61 Ki# 61 MSH2 61 VIPR2 61 p# MAPK 61 AlloMap 61 Bezielle 61 LNCaP cells 61 flavopiridol 61 germline mutations 61 metastatic malignant 61 hepatocellular carcinomas 61 methylation patterns 61 Ceflatonin 61 Leydig cells 61 myelofibrosis polycythemia vera 61 thalidomide Thalomid 61 TMPRSS2 ERG 61 tumor histology 61 FGFR1 61 haematologic 61 myeloid 61 c myc 61 constitutively expressed 61 mesenchymal cell 61 peripheral blood mononuclear 61 selective kinase inhibitor 61 papillary renal cell carcinoma 61 genotypic 61 gastrointestinal stromal tumor GIST 61 TP# mutations 61 qRT PCR 61 ADAMTS# 61 prostate cancer PCa 61 alefacept 61 HNSCC 61 CYT# potent vascular disrupting 61 interferon IFN 61 circadian genes 61 CDK inhibitor 61 refractory chronic lymphocytic 61 TAp# 61 castration resistant prostate cancer 61 HER-2/neu 61 gastrointestinal stromal tumors 61 somatostatin 61 replicon 61 CYP #D# 61 caveolin 1 61 IFN γ 61 TLE3 61 myeloproliferative disorders 61 HLA DQ2 61 rs# [004] 61 Factor Receptor 61 antibody MAb 61 receptor inhibitor 61 heavily pretreated 61 transfected cells 61 PI3K delta 61 malignant lymphoma 61 coding genes 61 ATL# [001] 61 coexpression 61 mRNA expression 61 Estrogen receptor 61 castrate resistant 61 antiangiogenic therapy 61 mutated KRAS 61 ELISPOT assay 61 CXCR4 60 IL 1ß 60 ATTR CM 60 functional polymorphism 60 beta actin 60 MAGE A3 ASCI 60 IFN α 60 progesterone receptor 60 Pralatrexate 60 antisense inhibitors 60 colorectal carcinoma 60 BRAF mutations 60 transplantation HSCT 60 Treg cell 60 KRAS BRAF 60 COX2 60 Septin9 60 K ras mutation 60 myeloperoxidase 60 hematopoietic 60 gene polymorphisms 60 IL 1beta 60 breast cancer subtypes 60 PTHrP 60 bucindolol 60 gastrointestinal stromal tumors GIST 60 PCa 60 GLI1 60 anti CD3 60 alternatively spliced 60 FOLFOX chemotherapy 60 CD4 + CD# 60 chromosomal rearrangement 60 Akt activation 60 lymphocytic 60 Azedra 60 Epratuzumab 60 TGF β 60 HbF 60 thyroglobulin 60 glucocorticoid receptor 60 miR #a [001] 60 IGFBP2 60 tumor antigen 60 platelet reactivity 60 HER2 receptor 60 synuclein 60 P selectin 60 leukemic cell 60 elacytarabine 60 cTnI 60 Dasatinib 60 microsatellite instability 60 PBMCs 60 molecular biomarkers 60 GPx 60 GBM tumors 60 p# activation 60 MEFs 60 JAK2 enzyme 60 APOPTONE 60 HSCT 60 NS5A 60 leukemic stem cells 60 Leydig cell 60 Cytochrome P# 60 sarcomatoid 60 interferon γ 60 lymph node metastasis 60 Cervista HPV HR 60 fosbretabulin 60 syngeneic 60 S#A# [002] 60 mCRC 60 Vidaza azacitidine 60 cytotoxin 60 cell lymphoma ALCL 60 adenoviral 60 HepG2 cells 60 lung adenocarcinomas 60 pheochromocytoma 60 Haptoglobin 60 HGS ETR1 60 tumor xenograft models 60 isoenzyme 60 mGlu2 3 60 imatinib Gleevec 60 CpG 60 hypoxia inducible factor 60 colorectal carcinomas 60 liver metastasis 60 inactivating mutations 60 Smad3 60 GRNCM1 60 pomalidomide 60 ERK1 2 60 missense mutations 60 presymptomatic 60 osteoclast 60 DEAR1 60 PITX2 60 mutant allele 60 cytomegalovirus CMV 60 galectin 3 60 tubulin inhibitor 60 colon carcinoma 60 LDL receptor 60 targeting CD# 60 mTOR mammalian target 60 TMEM#B 60 p# INK4a 60 carcinoid 60 Dysregulation 60 mediated apoptosis 60 follicular lymphoma FL 60 pDCs 60 PI3K Akt 60 CagA 60 Polymorphisms 60 breast carcinomas 60 APOL1 60 myeloproliferative diseases 60 histopathologic 60 lactate dehydrogenase LDH 60 gastric carcinomas 60 PPARγ 60 putative biomarkers 60 hydroxylase 60 vimentin 60 azacytidine 60 xenograft models 60 colony stimulating factor 60 EGFR expression 60 Chemokine Receptor 60 clusterin 60 MDM2 60 prognostic factor 60 metastatic neuroendocrine tumors 60 immunostaining 60 IL #E 60 Macrophage 60 MMP# 60 PDE#A 60 IL 1β 60 IgG1 60 3'UTR 60 antiproliferative effects 60 cells transfected 60 mediated inhibition 60 CTAP# Capsules 60 CD#c 60 CEACAM1 60 renal fibrosis 60 apoptotic pathway 60 miR #a [002] 60 EGF receptor 60 glioblastoma cells 60 HDACi 60 genetic polymorphisms 60 plasmacytoid dendritic cells 60 Posiphen 60 cediranib 60 bFGF 60 stably transfected 60 Sipuleucel T 60 histological subtype 60 NFkB 60 endostatin 60 immunomodulation 60 microarray experiments 60 Upregulation 60 CYP#A# [002] 60 neoplastic cells 60 neurite outgrowth 60 castrate resistant prostate cancer 60 KIT mutations 60 rs# [002] 60 Progenitor Cells 60 induces apoptosis 60 HER3 60 Phenoptin 60 prognostic significance 60 CCR7 60 EGFR TKI 60 CYP#D# 60 androgen independent 60 GATA3 60 LRAT 60 prostate adenocarcinoma 60 HIF 1α 60 proteomic analysis 59 Fas ligand 59 Bortezomib 59 Rap1 59 GRP# 59 methyltransferase 59 E cadherin expression 59 rhIL 7 59 c MET 59 breast cancer metastasis 59 hepatic fibrosis 59 HLA DR4 59 chronic eosinophilic leukemia 59 CD# expressing 59 pancreatic ductal adenocarcinoma 59 EGFR receptor 59 MMP inhibitors 59 DLC1 59 TGFß 59 P#X# 59 MAb 59 allogeneic stem cell 59 selective inhibitors 59 NSCLC 59 transcriptionally 59 NY ESO 59 OCT4 59 radiosensitivity 59 soluble tumor necrosis 59 Neurogenesis 59 TNFa 59 colorectal liver metastases 59 Stat5 59 osteogenic 59 ADPKD 59 MIF protein 59 Blinatumomab 59 trastuzumab Herceptin ® 59 HCV protease 59 leukaemic stem cells 59 EML4 ALK 59 liposomal doxorubicin 59 PhG alpha 1 59 tumor suppressor protein 59 RAS RAF MEK 59 Fc gamma receptor 59 estrogen receptor beta 59 M#V mutation 59 Lp PLA 2 59 Hypoxia Inducible Factor 59 Tie2 59 COL#A# 59 induce apoptosis 59 transcriptional activation 59 Zolinza 59 vitro experiments 59 Akt1 59 histone acetylation 59 oxysterols 59 progesterone receptor PR 59 bleomycin 59 eNOS 59 myeloid cells 59 matrix metalloproteinase 59 lymphocyte 59 ImmuKnow 59 micro RNA 59 potently inhibited 59 MGUS 59 metastatic colorectal 59 B Raf 59 hematopoietic cells 59 HLA DR 59 Interferon Beta 59 ALK mutations 59 miR #b [001] 59 oncogenesis 59 HDAC2 59 Mutation Analysis 59 NPM1 mutation 59 somatic mutations 59 ERCC1 59 SGLT2 59 chemoresistant 59 HGPIN 59 NFKBIA 59 TGFBR1 * 6A 59 pharmacokinetic interactions 59 CLL cells 59 proteasome inhibitor 59 N Myc 59 erythropoietic 59 HEK# cells 59 H#K#me# 59 AST ALT 59 gene expression profiles 59 anti fibrotic 59 estrogen receptor 59 Mesenchymal 59 nonsmall cell lung cancer 59 leukemia AML 59 Trp p8 59 premalignant 59 iNOS 59 multipotent 59 catenin 59 glioblastoma tumors 59 mimetics 59 Histologic 59 lymphoid tumors 59 carcinoid tumors 59 transduced 59 evolutionarily conserved 59 malignant nodules 59 chemokine receptor 59 cytokeratin 59 PARP inhibition 59 B lymphocyte 59 imatinib Gleevec ® 59 riociguat 59 TNF α 59 HGS ETR2 59 Lymph node 59 chemosensitivity 59 immunoregulatory 59 β catenin 59 ELISPOT 59 genomic biomarker 59 protein tyrosine phosphatase 1B 59 RNase L 59 thyrotropin 59 PPARgamma 59 pharmacogenetic 59 SPINK1 59 HAAH 59 PCA3 gene 59 pancreatic endocrine 59 metastatic RCC 59 chemopreventive agent 59 miRview ™ squamous 59 ZNF# 59 HER2 gene 59 IL #R 59 pituitary hormones 59 GAP #B# 59 immunohistochemical staining 59 BRAF V#E 59 cAMP signaling 59 K#N 59 natriuretic peptide 59 Corgentin 59 RT qPCR 59 prognostic indicator 59 hematopoietic stem cell 59 poor metabolizers 59 hA# 59 cytogenic 59 poly ADP ribose polymerase 59 plasma kallikrein 59 HBV vaccine 59 phosphate S1P 59 relapsed MM 59 Fibroblast 59 MDR1 59 acinar cells 59 p#Kip# 59 Tamibarotene 59 histologic 59 Phase #b/#a trial 59 HBsAg 59 hyperactivated 59 Her2 59 pan HDAC inhibitor 59 tumorigenesis 59 NF kB pathway 59 Enzastaurin 59 AAV2 59 CDK4 59 BRAF gene 59 HER2 positive metastatic breast 59 Tyrosine Kinase Inhibitor 59 ALK inhibitors 59 B7 H3 59 brostallicin 59 Cyclin E 59 FOXP3 59 TGF ß 59 chronic lymphocytic leukemia CLL 59 Cytogenetic 59 metaplasia 59 Transcription Factor 59 essential thrombocythemia 59 STK# [002] 59 generalized vitiligo 59 mRNA transcripts 59 B CLL 59 PAR1 59 anaplastic lymphoma kinase ALK 59 HQK 59 Pegylated 59 TCF#L# 59 CCR1 59 medically inoperable 59 VEGF receptor 59 paraganglioma 59 MLL AF9 59 synovial tissue 59 hedgehog pathway 59 EGFR mutant 59 ELISpot 59 histopathological 59 ERa 59 PDGFR 59 pharmacodynamic effects 59 TP# gene 59 telomerase reverse transcriptase 59 cytokines IL 59 p# deficient 59 cytotoxicity assays 59 IDH2 59 Sertoli cell 59 proinflammatory cytokine 59 Bucindolol 59 murine models 59 ESR1 59 ZOLINZA 59 polymorphisms 59 VE cadherin 59 receptor tyrosine kinase 59 transthyretin amyloidosis 59 myeloproliferative neoplasms 59 immunocompetent 59 cyclin dependent kinase inhibitor 59 PC# cells 59 protein tyrosine phosphatase 59 pharmacodynamic endpoints 59 monocytes macrophages 59 ALK inhibitor 59 Carfilzomib 59 gene loci 59 cell adhesion molecule 59 Cytotoxic T 59 immunoreactivity 59 CC genotype 59 small molecule activators 59 uricase 59 #beta HSD1 59 Th2 cytokines 59 ribosomal proteins 59 HLA DRB1 * 59 receptor mediated endocytosis 58 Xelox 58 cell lymphomas 58 CHO cells 58 activated lymphocytes 58 serotonin receptor 58 rs# [001] 58 prostate epithelial cells 58 ERK pathway 58 TERT 58 seliciclib 58 myeloma cells 58 thyroid hormone receptor 58 erlotinib Tarceva ® 58 PXD# 58 Wnt signaling pathway 58 bladder carcinoma 58 FUS1 58 causal variants 58 VEGFR2 58 HCV replicon 58 E. faecalis 58 β cells 58 microRNAs miRNAs 58 histone deacetylases 58 enzastaurin 58 VSV G 58 secretory pathway 58 reticulocytes 58 humanized anti 58 IGFBP 3 58 cis regulatory 58 MYCN amplification 58 gonadotropins 58 Annamycin 58 HBeAg negative 58 AMACR 58 VeriStrat 58 p# alpha [001] 58 perilipin 58 BCR ABL1 58 Lenalidomide 58 4E BP1 58 Trastuzumab 58 leukemia CLL 58 basal cell nevus syndrome 58 pancreatic neuroendocrine tumors 58 antisense inhibition 58 radiolabeled 58 Zavesca R 58 polycythemia vera PV 58 troponin T 58 replicase 58 glioma cells 58 micrometastasis 58 medullary thyroid cancer 58 chimerism 58 Mantle Cell Lymphoma 58 IgM antibody 58 seminoma 58 CBLC# 58 thymalfasin 58 IGF1R 58 potently inhibit 58 situ hybridization 58 CCX# 58 normal karyotype 58 multigene expression test 58 histone deacetylase HDAC inhibitor 58 granulocyte 58 Telintra 58 NQO1 58 transcriptional regulation 58 monocyte derived 58 diabetic nephropathy 58 transgenic mice expressing 58 Lymphocytes 58 #q#.# [001] 58 pharmacodynamic PD 58 CpG island 58 CEQ# 58 P cadherin 58 WNK1 58 squamous cell lung cancer 58 matrix metalloproteinases MMPs 58 neoplastic 58 Pharmacokinetics PK 58 p# mutations 58 missense mutation 58 oncoprotein 58 aT cell 58 herpesviruses 58 pT2 58 hematopoietic cell 58 SERMs 58 pediatric acute lymphoblastic 58 multinucleated 58 protein phosphorylation 58 alpha fetoprotein AFP 58 pegylated 58 pharmacokinetic PK 58 pertussis toxin 58 CHD7 58 MTT assay 58 P. patens 58 rNAPc2 58 gastric carcinogenesis 58 differentiated thyroid 58 DNA methylation patterns 58 IL #p# 58 alkylating agent 58 gene inactivation 58 pancreatic carcinoma 58 CD# + [002] 58 precancerous tissues 58 MUC1 58 Mutational 58 Aurora kinase 58 mda 7 58 pro angiogenic 58 CD8 + 58 MET amplification 58 #T# L1 58 TRIOLEX 58 Wwox 58 CD# CD# 58 alvespimycin 58 non coding RNA 58 transthyretin 58 hypereosinophilic syndrome 58 APTIMA HPV 58 intravesical therapy 58 mitogen activated protein kinase 58 genes CYP#C# 58 immunoblotting 58 acadesine 58 PTEN gene 58 homodimers 58 sDNA 58 T2DM 58 clinicopathological 58 MYCN 58 druggable targets 58 serine threonine kinase 58 localized renal 58 5q deletion 58 IgG4 58 rhFVIIa 58 DNA methyltransferases 58 Everolimus 58 miRNA genes 58 thymocytes 58 miRNA molecules 58 serine protease 58 ENMD # 58 granulocytes 58 surrogate endpoint 58 Evoltra ® 58 biomarker 58 Omacetaxine mepesuccinate 58 PI3 kinase 58 aCGH 58 receptor blocker 58 allogeneic HSCT 58 neutralizing antibody 58 INCB# [001] 58 figitumumab 58 monocyte chemotactic protein 58 MYH9 gene 58 PAX5 58 genotypic resistance 58 QTL mapping 58 cDNAs 58 PlGF 58 standard chemotherapy regimens 58 subcellular localization 58 #p# [003] 58 BRIM3 58 Genotypes 58 JAK2 mutation 58 antitumor 58 potent inhibition 58 pharmacodynamic markers 58 chitinase 58 preclinical efficacy 58 methylated DNA 58 ADAM# 58 aurora kinase 58 Squamous 58 HER2 HER3 58 vandetanib 58 Aurora Kinase 58 Onconase 58 nonalcoholic steatohepatitis NASH 58 olaparib 58 HER2 positive cancers 58 C#BL 6 mice 58 Oncotype 58 heterozygous 58 DXL# 58 GNAQ 58 prognostic indicators 58 heterologous 58 KRAS mutated 58 unmutated 58 SLC#A# [002] 58 oligodendroglioma 58 orthologs 58 XYOTAX TM 58 E selectin 58 leukemia ALL 58 SNP rs# [001] 58 FasL 58 K#R [002] 58 FISH fluorescence 58 Hepatocellular Carcinoma 58 EGFR gene 58 inhibin B 58 mapatumumab 58 thymosin 58 Dapagliflozin 58 nonmetastatic 58 peroxisome proliferator activated 58 vemurafenib 58 protein kinase C 58 calcineurin inhibitors 58 cynomolgus monkeys 58 Lymphocyte 58 estrogen receptor negative 58 anaplastic lymphoma kinase 58 GPR# [002] 58 epigenetic mechanisms 58 autoantibody 58 CTNNB1 58 HER2 amplification 58 FGFR4 58 Aplidin 58 Amrubicin 58 preclinically 58 HERmark assay 58 Prodarsan ® 58 premalignant lesions 58 osteocalcin 58 NFκB 58 beta subunit 58 UCP2 58 trophoblast 58 C1q 58 #S rRNA gene 58 monocytic 58 fluoropyrimidine oxaliplatin 58 lymphomas 58 EGFR TKIs 58 genes encoding 58 NEUVENGE 58 overexpressing 58 Kahalalide F 58 MLH1 58 HCV SPRINT 58 CD# monoclonal antibody 58 endogenous ligands 58 castration resistant